BioPharma Resources

Drug Trial Radar · NCT06717347

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,046 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,046

Planned (sponsor's estimate)

Start

Jan 27, 2025

Primary completion

Jul 2, 2029

Study completion Mar 29, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • Zilovertamab vedotinBiological

    IV infusion

  • RituximabBiological

    IV infusion

  • CyclophosphamideDrug

    IV infusion

  • DoxorubicinDrug

    IV infusion

  • Rituximab BiosimilarBiological

    IV infusion

  • PrednisoneDrug

    Per Approved Product Label

  • PrednisoloneDrug

    Oral administration

  • VincristineDrug

    IV infusion

  • Rescue medicationDrug

    Participants receive rescue medication per approved product label. The rescue medication is granulocyte colony-stimulating factor (G-CSF).

  • MethylprednisoloneDrug

    Per Approved Product Label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to ~ 50 months

Locations

289 sites in 35 countries. Site status is shown where the registry gives one.

  • USA Mitchell Cancer Institute ( Site 0173)

    Mobile, Alabama · Recruiting

  • Banner MD Anderson Cancer Center ( Site 0165)

    Gilbert, Arizona · Recruiting

  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)

    Phoenix, Arizona · Recruiting

  • The University of Arizona Cancer Center - North Campus ( Site 0124)

    Tucson, Arizona · Recruiting

  • Providence Medical Foundation-Oncology ( Site 0168)

    Fullerton, California · Recruiting

  • MemorialCare Health System - Long Beach Medical Center ( Site 9559)

    Long Beach, California · Recruiting

  • Cancer Blood and Specialty Clinic ( Site 0109)

    Los Alamitos, California · Recruiting

  • Cedars-Sinai Medical Center ( Site 0115)

    Los Angeles, California · Recruiting

  • Pacific Hematology Oncology Associates ( Site 0131)

    San Francisco, California · Recruiting

  • Lutheran Hospital - Cancer Centers of Colorado ( Site 0180)

    Golden, Colorado · Recruiting

  • Clermont Oncology Center ( Site 0182)

    Clermont, Florida · Recruiting

  • Bioresearch Partner ( Site 0157)

    Hialeah, Florida · Recruiting

  • Orlando Health Cancer Institute ( Site 0169)

    Ocoee, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center ( Site 0172)

    Orange City, Florida · Recruiting

  • Tampa General Hospital ( Site 0134)

    Tampa, Florida · Recruiting

  • University Cancer & Blood Center, LLC ( Site 0141)

    Athens, Georgia · Recruiting

  • Hope and Healing Cancer Services ( Site 9511)

    Hinsdale, Illinois · Recruiting

  • Edward Cancer Center ( Site 0197)

    Naperville, Illinois · Recruiting

  • Cancer Care Specialists of Illinois ( Site 0152)

    O'Fallon, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology ( Site 0149)

    Fort Wayne, Indiana · Recruiting

  • Cotton O'Neil Cancer Center ( Site 0108)

    Topeka, Kansas · Completed

  • University of Kentucky ( Site 0106)

    Lexington, Kentucky · Recruiting

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163)

    Louisville, Kentucky · Recruiting

  • Owensboro Medical Health System ( Site 0195)

    Owensboro, Kentucky · Recruiting

  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184)

    Alexandria, Louisiana · Recruiting

  • American Oncology Partners, P.A. ( Site 0185)

    Bethesda, Maryland · Recruiting

  • Maryland Oncology Hematology (MOH) ( Site 8004)

    Columbia, Maryland · Recruiting

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545)

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute ( Site 0174)

    Detroit, Michigan · Recruiting

  • Corewell Health ( Site 0130)

    Grand Rapids, Michigan · Recruiting

  • Central Michigan University - Saginaw ( Site 0198)

    Saginaw, Michigan · Recruiting

  • The University of Mississippi Medical Center ( Site 0161)

    Jackson, Mississippi · Recruiting

  • Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166)

    Bridgeton, Missouri · Recruiting

  • University of Missouri Hospital ( Site 0175)

    Columbia, Missouri · Recruiting

  • Truman Medical Center ( Site 0122)

    Kansas City, Missouri · Recruiting

  • Oncology and Hematology Associates ( Site 9546)

    Springfield, Missouri · Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178)

    Billings, Montana · Recruiting

  • OptumCare Cancer Care ( Site 0121)

    Las Vegas, Nevada · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 0113)

    Las Vegas, Nevada · Recruiting

  • Cancer Care Specialists ( Site 9582)

    Reno, Nevada · Recruiting

Showing 40 of 289 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.